TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29735019
Drug: EPA+DHA therapy
Normalized name: eicosapentaenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA+DHA therapy (2.5 g/d)
Study: 22656676
Drug: Hyperbaric ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric ropivacaine (11.25mg) + 2mL dextrose (5mg.mL(‐1))
Study: 18729814
Drug: Carnosine (beta‐alanyl‐L‐histidine)
Normalized name: histidinal, L-
DrugBank: Carnosine (DB11695)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnosine (beta‐alanyl‐L‐histidine) as a food additive
Study: 12414399
Drug: HOTL (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOTL (daily wear)
Study: 12414399
Drug: Control lens
Normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control lens (daily wear)
Study: 12414399
Drug: Both lenses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both lenses (daily wear)
Study: 10359479
Drug: ipsapirone 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipsapirone 0.3 mg/kg
Study: 1782977
Drug: Buccal nitroglycerin
Normalized name: nitroglycerin Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal nitroglycerin every 4 hours
Study: 1782977
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin for 24 hours
Study: 23011771
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 µg once-daily
Study: 15134695
Drug: Glutamate (1
Normalized name: Glutamate (13-N)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamate (1 M) injection into the MAR or right SP
Study: 15134695
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline injection into the MAR or SP
Study: 11157009
Drug: FEC 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC 50 (fluorouracil 500 mg/m2, epirubicin 50 mg/m2, cyclophosphamide 500 mg/m2)
Study: 11157009
Drug: FEC 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC 100 (fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2)
Study: 2522008
Drug: Amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5 to 10 mg qd, mean 9 mg/d)
Study: 28416247
Drug: Adaptive cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive cardiac resynchronization therapy (aCRT)
Study: 21507028
Drug: DNK333 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNK333 25 mg b.d.
Study: 21507028
Drug: DNK333 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNK333 100 mg b.d.
Study: 21507028
Drug: DNK333 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNK333 25 mg b.d. (Trial 2)
Study: 17021083
Drug: High-dose alpha2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose alpha2b interferon (6 million units/day) plus ribavirin (600 to 800 mg/day)
Study: 17021083
Drug: Ribavirin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (600 to 800 mg/day)
Study: 17021083
Drug: High-dose alpha2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose alpha2b interferon plus ribavirin
Study: 10981565
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir (10 mg/kg three times daily for 9 days) + prednisolone (60 mg per day with progressive reduction for 21 days)
Study: 10981565
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia (6-12 ml bupivacaine (0.25%) every 6-8 or 12 h) + methylprednisolone (40 mg every 3-4 days by epidural catheter for 7 to 21 days)
Study: 9049576
Drug: Ibuprofen (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (7.5 mg/kg per dose)
Study: 9049576
Drug: Aspirin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (10 mg/kg/dose)
Study: 9049576
Drug: Paracetamol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (10 mg/kg per dose)
Study: 8325065
Drug: Oral theophylline
Normalized name: theophylline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline (400 mg for 2 weeks, followed by 600 mg for 2 weeks)
Study: 15094031
Drug: standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard treatment + soma
Study: 15094031
Drug: standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard treatment + relaxation training
Study: 11765290
Drug: Placebo, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 5 mg, 10 mg, 15 mg (various doses)
Study: 9290370
Drug: DACE group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: DACE group (drainage, air injection, cryotherapy, and explant)
Study: 9290370
Drug: CDAE group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDAE group (cryotherapy, drainage, air injection, and explant)
Study: 3521524
Drug: Doxepin hydrochloride
Normalized name: Doxepin Hydrochloride
DrugBank: Doxepin (DB01142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxepin hydrochloride (mean maximal dose: 105 mg)
Study: 3521524
Drug: Placebo (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mean maximal dose: 128 mg)
Study: 28566124
Drug: Topical melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical melatonin 12.5%
Study: 28566124
Drug: Topical melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical melatonin 0.5% and 2.5%
Study: 28566124
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and no treatment
Study: 26230471
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 5 mmol/L magnesium sulfate (MgSO4) solution for 14 days
Study: 22357799
Drug: Therapist-led exercise
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-led exercise therapy group (C1, n = 16)
Study: 22357799
Drug: Non-therapist-led exercise
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-therapist-led exercise therapy group (C2, n = 16)
Study: 9495978
Drug: Aspirin taken
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin taken preventively before adverse reactions of alpha-IFN
Study: 9495978
Drug: Traditional routines
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional routines of aspirin administration
Study: 28477289
Drug: Atomoxetine (1.2–1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (1.2–1.8 mg/kg/day) for 1 year, followed by randomization to atomoxetine for 6 months (n=81)
Study: 28477289
Drug: Atomoxetine (80–100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (80–100 mg/day) for 6 months, followed by randomization to atomoxetine for 6 months (n=266)
Study: 24807650
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of insurance intervention and capitation budget with pay-for-performance
Study: 9193431
Drug: Ser447-Stop allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ser447-Stop allele carriers using beta-blockers
Study: 9193431
Drug: Ser447-Stop allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ser447-Stop allele carriers not using beta-blockers
Study: 1604251
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone (1000 mg)
Study: 1604251
Drug: Low-dose methylprednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methylprednisolone (375 mg)
Study: 23101257
Drug: Combined antihypertensive
Normalized name: ANTIHYPERTENSIVE COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antihypertensive therapy (long-acting verapamil combined with slow-release indapamide)
Study: 23101257
Drug: Combined antihypertensive
Normalized name: ANTIHYPERTENSIVE COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antihypertensive therapy (long-acting verapamil combined with enalapril)
Study: 19446147
Drug: Standard-dose prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose prednisone regimen (1 mg/kg daily)
Study: 19446147
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) combined with lower prednisone dose (0.5 mg/kg daily)
Study: 16447665
Drug: TCM and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM and western drugs (Control)
Study: 6945060
Drug: Vincristine (VCR)
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine (VCR) 2 mg/m2 on day 1 and Cyclophosphamide (CP) 450 mg/m2 on days 2 and 3 (two-drug regimen)
Study: 6945060
Drug: Vincristine (VCR)
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine (VCR) 2 mg/m2 on day 1, Cyclophosphamide (CP) 450 mg/m2 on days 2 and 3, and BCNU 50 mg on days 2 and 3 (three-drug regimen)
Study: 31580695
Drug: Combination Therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Therapy (IC + Dry Cupping)
Study: 28260863
Drug: Glimepiride in
Normalized name: Product containing glimepiride in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride in combination with rosuvastatin
Study: 28260863
Drug: Rosuvastatin in
Normalized name: Product containing rosuvastatin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin in combination with glimepiride
Study: 23676106
Drug: Oral metformin
Normalized name: metformin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metformin (250 mg three times daily in the first week, followed by 500 mg three times daily thereafter)
Study: 20972351
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg) for 6 months in patients with high baseline LDL-C (≥ 100 mg/dL)
Study: 20972351
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg) for 6 months in patients with low baseline LDL-C (< 100 mg/dL)
Study: 20361714
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of cardamom powder administered in two divided doses for 12 weeks
Study: 11282259
Drug: Memantine (0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (0.16 mg/kg)
Study: 7699618
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment strategies
Study: 3129807
Drug: DDAVP 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP 0.4 microgram kg‐1 intravenous (i.v.)
Study: 3129807
Drug: DDAVP 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP 0.4 microgram kg‐1 subcutaneous (s.c.)
Study: 28993287
Drug: Certified diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certified diabetes educators (CDEs) implementing standardized protocols to intensify treatment
Study: 26434249
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of APE (71.64-72.36 mg/day)
Study: 26434249
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of APE (119.64-120.36 mg/day)
Study: 26434249
Drug: Gemfibrozil (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (300 mg/day)
Study: 23552120
Drug: Spironolactone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25 mg thrice weekly after dialysis for 4 months)
Study: 18218298
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (dexibuprofen 400 mg by Emcure Pharmaceuticals)
Study: 18218298
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (dexibuprofen 400 mg by Genus Pharmaceuticals)
Study: 16272449
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg intravenous hydrocortisone every 6 h
Study: 14620923
Drug: Candesartan (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (8 mg daily)
Study: 12808270
Drug: Candesartan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan plus probucol (500 mg daily)
Study: 1681355
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (atenolol plus isosorbide mononitrate and nifedipine)
Study: 6307330
Drug: Delta-9-tetrahydrocannabinol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta-9-tetrahydrocannabinol (0.5 mg i.v.)
Study: 6307330
Drug: Delta-9-tetrahydrocannabinol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta-9-tetrahydrocannabinol (1 mg i.v.)
Study: 28644680
Drug: SCORS‐G scales
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCORS‐G scales
Study: 28644680
Drug: SCORS‐G
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCORS‐G
Study: 20554708
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 5 mg annually
Study: 18936231
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (240 mg)
Study: 11310904
Drug: Non-EDTA sedative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-EDTA sedative agents
Study: 8612407
Drug: Reconstituted high-density
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconstituted high-density lipoprotein preparation (2 mg/mL)
Study: 1348620
Drug: Vecuronium 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.015 mg/kg (priming) followed by 0.285 mg/kg
Study: 1348620
Drug: Vecuronium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.3 mg/kg (single dose)
Study: 1348620
Drug: Vecuronium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.3 mg/kg (both groups)
Study: 1348620
Drug: Edrophonium 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.75 mg/kg for reversal
Study: 20415689
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart 50 (BIAsp 50)
Study: 20415689
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart 70 (BIAsp 70)
Study: 19066382
Drug: Dexamethasone 0.05
Normalized name: dexamethasone 0.05 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.05 mg/kg
Study: 16029524
Drug: Early conservative
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early conservative treatment
Study: 10647168
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy treatment based on classification
Study: 1341133
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of a mixture including 3 ml of 0.5% bupivacaine, 1 ml fentanyl in 1 ml of 10% dextrose solution (Group II)
Study: 1341133
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of a mixture including 3 ml of 0.5% bupivacaine, 0.15 mg clonidine (Group IV)
Study: 1341133
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of 0.5% bupivacaine at 5 degrees C (Group VI)
Study: 1341133
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of 0.5% bupivacaine at 27 degrees C (Group I)
Study: 1341133
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of 0.5% bupivacaine at 20 degrees C (Group V)
Study: 1341133
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of a mixture including 3 ml of 0.5% bupivacaine, 0.20 mg adrenaline (Group III)
Study: 22357252
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m²) plus carboplatin (AUC5) followed by radiation (50.4 Gy) (arm-A)
Study: 22357252
Drug: Simultaneous radiochemotherapy
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous radiochemotherapy with cisplatin (40 mg/m²/week) (arm-B)
Study: 17397698
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) plus slow-release morphine
Study: 17397698
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus slow-release morphine
Study: 11747767
Drug: Domestic anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Domestic anastrozole tablet (1 mg)
Study: 11747767
Drug: Imported anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imported anastrozole tablet (1 mg)
Study: 8422222
Drug: Alprazolam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (mean daily dose of 5.7 mg)
Study: 8422222
Drug: Imipramine hydrochloride
Normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imipramine hydrochloride (175 mg/d)
Study: 3312502
Drug: Labetalol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (100 to 800 mg BID)
Study: 3312502
Drug: Labetalol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol + Diuretic
Study: 3312502
Drug: Propranolol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol + Diuretic
Study: 26153271
Drug: MPCs (rexlemestrocel-L)
Normalized name: Rexlemestrocel-L
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPCs (rexlemestrocel-L) 0.3 × 10(6)/kg, n = 15
Study: 26153271
Drug: MPCs (rexlemestrocel-L)
Normalized name: Rexlemestrocel-L
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPCs (rexlemestrocel-L) 1.0 × 10(6)/kg, n = 15
Study: 26153271
Drug: MPCs (rexlemestrocel-L)
Normalized name: Rexlemestrocel-L
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPCs (rexlemestrocel-L) 2.0 × 10(6)/kg, n = 15
Study: 21823276
Drug: Compound Danshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Danshen dripping pill (medicine group)
Study: 11986453
Drug: Zinc syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc syrup
Study: 11986453
Drug: Zinc syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc syrup and vitamin A
Study: 11986453
Drug: Zinc syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc syrup (caretaker administered)
Study: 7666102
Drug: Dexamethasone plus
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone plus granisetron (dexamethasone 8 mg IV + granisetron 3 mg IV)
Study: 7666102
Drug: Granisetron alone
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron alone (3 mg IV)
Study: 7666102
Drug: Dexamethasone alone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone alone (8 mg IV)
Study: 2548660
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (600 mg in 3 divided doses p.o.)
Study: 28038376
Drug: Intramuscular fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular fat fractions
Study: 22046702
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine (K)
Study: 22046702
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (M)
Study: 22046702
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam and ketamine combination (MK)
Study: 15677433
Drug: Conventional antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antipsychotics or risperidone
Study: 8198905
Drug: 1.5% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% lignocaine 15 ml with adrenaline infiltrated into the proposed wound line 3 min before incision
Study: 8198905
Drug: Lignocaine 15
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 15 ml with adrenaline infiltrated into the wound on closure
Study: 31420064
Drug: Dexamethasone (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (intramuscular regimen)
Study: 24574052
Drug: Levofloxacin (LFX)
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin (LFX) 500 mg, once daily (o.d.)
Study: 24574052
Drug: Placebo, once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once daily (o.d.)
Study: 21383263
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (cognitive behavior therapy plus switch to a different antidepressant medication)
Study: 7530706
Drug: Inhaled substance
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled substance P (SP) at doses of 0.25-8 mg/ml
Study: 30309257
Drug: 12-month maintenance
Normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 12-month maintenance treatment
Study: 21434488
Drug: Tramadol/Paracetamol (TP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol/Paracetamol (TP 37.5/325 mg)
Study: 21434488
Drug: Paracetamol/Codeine (CP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol/Codeine (CP 30/500 mg)
Study: 19097715
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg raloxifene (RLX)
Study: 19097715
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg percutaneous 17beta-estradiol associated to 60 mg raloxifene (RLX+E2)
Study: 12775172
Drug: Access to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access to the program (treatment group)